FibroGen (FGEN) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
FibroGen Reports First Quarter 2023 Financial Results
May 8, 2023 4:01 PM EDTÂ Topline Data From Four Phase 3 Trials Expected Through 3Q 2023
 Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
Entered Into Exclusive License for FOR46 with Fortis Therapeutics
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the companys recent developments.
We look forward to reporting topline data from four pivotal phase 3 trials through the... More
